SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

Insulet’s chief growth officer said: “colour has the power to differentiate a brand,” with mango orange adorning Omnipod’s ...

Tandem Diabetes Care says the Food and Drug Administration (FDA) has cleared its smartphone app to program and cancel insulin doses from the t:slim X2 insulin pump. The company claims it's the first ...

It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...

MARKHAM, Ontario--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

Photo: Matt Harbicht/Getty Images for Tandem Diabetes Care (Getty Images) At least 224 people have been injured after an iPhone app called t:connect drained the battery on its accompanying insulin ...

The US Food and Drug Administration (FDA) has issued a Class I recall for the t:connect mobile app on iOS, which is used to monitor and control the t:slim X2 insulin pump used by people with diabetes.

Blair Brenner has been an insulin-dependent Type 1 diabetic for more than 40 years and hasn’t always had the disease under control. She’s been hospitalized for diabetic complications and found that ...

Researchers at the University of Washington School of Medicine recently published a first-of-its-kind study looking at an oft-overlooked problem facing people with diabetes who use insulin pump ...

Mattel’s new Barbie doll is a Type 1 diabetic with an insulin pump and glucose monitor on her arm. The new brunette Barbie is the latest in a line of dolls the American toy giant has rolled out, ...

Pump vs control sites had greater vessel density, fibrosis, fibrinogen, and inflammation including eosinophils, insulin-like-growth factor-1 (IGF-1), and transforming growth factor (TGF) β-3, as well ...